Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,199.20
(
1.73%
)
Dow Jones
50,461.68
(
-0.23%
)
Brent Oil
96.54
(
-4.58%
)
Bitcoin
76,011.44
(
-1.63%
)
News Focus
News Focus
Post# of 257640
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123018
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 92890

Monday, 03/22/2010 6:04:37 AM

Monday, March 22, 2010 6:04:37 AM

Post# of 257640
So, after careful consideration, the FDA accepted the Copaxone application from NVS/MNTA for review even though the FDA knew from the start that an ANDA was an inappropriate regulatory pathway for this application? You’re still not making any sense, IMHO.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today